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Objectives: Patients with intractable spasticity treated with intrathecal baclofen (ITB) need regular evaluation and aftercare in
an outpatient clinic or pain clinic setting. Logistically, this can be challenging. A solution could be to perform treatment at the
patient’s home setting. In the Netherlands, a project of the Dutch Healthcare Authority was initiated to deliver ambulatory ITB-
related services via a home-based Ambulant Care Clinic. This aftercare is performed by nurse practitioners (NP) with support
from a medical specialist. The scope of the study was to investigate the efﬁciency and safety of ITB-care for patients with
severe disabling spasticity in their home setting.
Materials and Methods: A retrospective analysis of prospectively collected data. Patients with congenital or acquired spastic-
ity were treated with ITB (1st April 2011 to January 1st 2016) using an implanted programmable pump system were referred
to the home-based Ambulant Care Clinic by various neuromodulation centers in the Netherlands. All study parameters were a
part of the standard intake and follow-up documentation.
Results: Of the 900 patients treated with ITB in the Netherlands, 239 were referred to the home-based Ambulant Care Clinic
and included in this study. Mean age was 45.5 (range 7–82) years; 52% lived at home; the average satisfaction score was
9 (scale 0–10); and 0.29% had (serious) adverse events (60% of clinical manifestations were prevented by remote double-check
control). Certiﬁcations for patient safety and quality standards were obtained.
Conclusions: The concept of ITB aftercare on location demonstrated efﬁcacy and safety in the described setting. For trouble-
shooting, close collaboration with a neuromodulation center is necessary and can be arranged in chain-based care.
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INTRODUCTION
It has been shown that the administration of intrathecal baclo-
fen (ITB) via an implantable drug delivery system provides a
reduction of intractable severe spasticity. Regarding long-term
use only data from observational studies are available; these
studies showed secondary beneﬁts including fewer side-effects,
improvement in activities of daily living, less sleep disturbance,
and fewer care needs (1–9).
Until now, long-term follow-up of ITB has only been performed in
a hospital setting. However, this is often inconvenient for severely
immobilized patients and sometimes makes it impossible to provide
therapy. Despite the advantages of ITB therapy, this inconvenience
may be one of the reasons for the substantial undertreatment
and/or an often “too late” initiation of ITB (5). These problems might
be reduced by performing ITB aftercare in the patient’s own sur-
roundings (e.g. at home, in a nursing home or in disabled commu-
nity). Therefore, we developed a home-based Ambulant Care Clinic
to provide high-level standard care in a close cooperation with some
of the neuromodulation centers.
We obtained recognition as a home-based Ambulant Care
Clinic of the Ministry of Health, Wellbeing, and Sport. For the pro-
vision of home-based specialized medical care, no regular
ﬁnancial reimbursement was available. However, since the Minis-
try offers ﬁnancial support for new projects to stimulate innova-
tions in healthcare, our “home-based Ambulatory Care Clinic
Neuromodulation” activity was accepted as an innovation project.
One of the requirements for approval of this project was the dem-
onstration of quality and safety.
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MATERIALS AND METHODS
We performed a retrospective analysis of prospectively col-
lected data, investigating the efﬁcacy and safety of delivery of
home-based ITB aftercare in the period of 1st April 2011 to
January 1st 2016.
The study was approved by the local Medical Ethical committee
(2018–1221). After referral to the home-based Ambulant Care Clinic,
patients gave consent for the treatment at the initial visit. Due to the
retrospective character of the study, the local Medical Ethical commit-
tee waived away the requirement to obtain informed consent.
Only patients with severe disabling spasticity were eligible, and
these were treated with ITB using an implanted programmable
pump system (SynchroMed II, Medtronic Inc., Minneapolis, MN,
USA) and referred to the home-based Ambulant Care Clinic by
neuromodulation centers. Patients had to have achieved a stabi-
lized dose for at least 3 months before their referral.
After referral for aftercare, there followed an initial visit from a
specialized physician and nurse practitioner (NP). During the visit,
the ITB aftercare on location concept was explained, and
informed consent and medical history were obtained, followed by
a physical examination and a read-out of the pump settings.
In addition to this, in the ﬁrst 3 years for the initial visit, we
used a standard questionnaire where patients were asked about
the burden of traveling to the center for their ITB aftercare. At the
following visits, we gathered information and entered it in the
electronic patient ﬁle including the reason for the visit, performed
activity, printouts of the programming pump, any (serious)
adverse events, complaints, annual patient satisfaction scores, and
travel time/distance to the center. We recorded the number of
pump reﬁll visits during the study period, as well as the additional
visits for dose adjustments.
Via an annually applied anonymous questionnaire, patients pro-
vided their feedback on the ITB management service and their
satisfaction level with the service. In case of ofﬁcial complaints,
we started a complaints procedure.
In our setting, we have chosen to work with nurse practitioners
(NP: Master’s Degree in Advanced Nursing Practice). In our country,
NP’s are allowed to perform medical tasks independently. They are
obliged to follow training every year. A reregistration will follow after
5 years only if all of the training requirements have been met. In the
ﬁrst 3 months working with ITB, the NP’s are trained on the job by a
medical specialist and an experienced nurse practitioner and work on
an observer basis. During the next year, they receive intensive super-
vision. In addition, weekly multidisciplinary patient meetings and
three monthly intervision sessions are held. During their work, the
NP’s are supervised by a medical specialist or a (colleague) NP10. The
team is available on call 24/7. For percutaneous pump reﬁlls, patients
were visited at least every 90 days as well as, if necessary, for dose
adjustments and/or troubleshooting. We performed visits at the
patient’s home, a nursing home, a community for disabled persons,
or (in case of a temporary stay) in the rehabilitation center or hospital.
One week before the appointment, a nurse practitioner pre-
pared the visit. The NP prescribed a baclofen solution and (after
being checked by a second nurse practitioner or medical supervi-
sor) and digitally sent the prescription to the pharmacy. After
receiving the medication, the NP checked the prescription and
medication label and stored the medication at room temperature.
Two to three days before the visit, the NP telephoned the patient
or caregiver to enquire about the clinical status of the patient;
if this was not stable, the condition was discussed with the
medical supervisor. On location, the NP made a brief note of medical
history (focusing on spasticity treatment), performed a physical exami-
nation, and used telemedicine (encrypted bi-directional video con-
nection via the 3G or 4G-broadband, Cisco Jabber Video Telepresence
software version 4.7, Visions Connected, Amsterdam, The Nether-
lands). The screen-to-screen connection gives the supervisor and
another NP or medical specialist access to communicate with the
patient and the NP on location, as well as remote visual control of the
prescription and the syringe label. After this, the connection was ter-
minated and the NP performed the reﬁll and/or dose adjustments
and programming procedures. After reﬁlling the pump under aseptic
conditions, the NPmade another telemedicine application for remote
visual control of the pump programming printout. If the supervisor
observed an error in programming, an immediate correction was
made. Occasionally, we video-recorded the procedure either at the
request of a physician or for training purposes. The NP documented
the results in the electronic patient ﬁle. The patient received a printout
of the pump programming session. Finally, the NP sent a consultation
letter to the patient’s physician(s). If requested, a brief consultation let-
ter was left behind after the visit (Fig. 5).
The equipment included a synthetic, washable three-compartment
trolley, separating sterile and nonsterile material, a box for medication
storage during transport, a pump programmer (N’Vision, Medtronic),
a mobile printer, a laptop, and a mobile telephone. The small laptop
computer had an integrated camera and a built-in dongle device all-
owing wireless broadband access. Also, the supervisor (based at the
headquarters of the ambulant clinic) was provided with a computer
with identical features.
Data Records
For safety management, we followed the Dutch Technical Agree-
ment 8009 ‘Safety management system for hospitals and organiza-
tions which administer hospital care. This embeds patient safety in
healthcare practices. It enables risk identiﬁcation, the implementation
of improvements and evaluations, and modiﬁcation of policies. It
also includes the ‘5 rights’, that is, the “right patient, right action,
right time, right cues, right reason” (10). The team adhered to these
rights: that is, used the appropriate concentration of medication and
the appropriate pump programming. Throughout the study, all seri-
ous adverse events (SAE) were recorded at each visit and discussed
at our 6-weekly multidisciplinary team progress meetings. A sub-
heading was made of the (S)AE that occurred due to surgery, as well
as hospital-related and long-term related complications.
All visits, telephone calls and patient consultations were
reported in an electronic patient dossier, including the referral let-
ter, physical examination, treatment, medication, and printouts of
the pump programming.
For prospective and retrospective risk management of near-inci-
dents, we applied the “Healthcare Failure Mode and Effect Analysis”
(HFMEA) of the “National Center for Patient Safety” (NCPS) (11). In
case of a high risk of frequency and severity of consequences, we
made an extensive PRISMA Medical analysis (Prevention Recovery
Information System for Monitoring and Analysis) (12) to manage
structural human errors in practice.
External Audits
A quality and safety certiﬁcation procedure was performed annually
by an independent professional inspection institute (KIWA, Rijswijk,
The Netherlands). The certiﬁcate demonstrates that the home-based
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Ambulant Care Clinic met the necessary requirements for efﬁcient and
safe management and veriﬁes that the related processes were cor-
rectly performed and in a way which enables the clinic to be sustain-
able. For the audit, the home-based Ambulant Care Clinic had to
describe all protocols and procedure descriptions together with
descriptive ﬂow charts. The hygiene audit process included a “spot
check” whereby the nurse practitioner (upon patient’s consent) was
accompanied and observed by a hygiene auditor. As a part of the
annual audit, the supervising pharmacist carried out an assessment of
medication delivery and transportation.
RESULTS
From 1st April 2011 to 1st January 2016, 239 patients of the
current total population of 900 patients were referred to the
home-based Ambulant Care Clinic. Table 1 presents the demo-
graphic and baseline characteristics. Multiple sclerosis (MS), cere-
bral palsy (CP), and spinal cord injury (SCI) were the most
frequently reported etiologies of spasticity.
At the start of the home-based Ambulatory Care Clinic, nine hos-
pitals in the Netherlands were treating patients with ITB. In addition
to the hospitals, there were also satellite centers, for example, reha-
bilitation centers reﬁlling and/or making dose adjustments. The
majority of patients live at home: 28% live in a nursing home and
20.1% live in a community for disabled persons.
Communications
At the start of the study, 3G broadband was used for online
videoconferencing. From 2014 onwards, 4G broadband was avail-
able and used. In the 3G broadband era, on 5 occasions, the con-
nection was insufﬁcient to establish a video feed. Three patients
allowed the use of their own WiFi; for two patients, the only solu-
tion for control was a real-time telephone call. At the end of 2014,
the telecommunication provider (KPN) delivered coverage to
98.4% of the inhabitants and 96% surface coverage throughout
the Netherlands. Since then, very few connection problems have
been encountered.
Feasibility
During the ﬁrst 3 years, 143 patients referred to the home-
based Ambulant Care Clinic were asked about the burden of trav-
eling (Fig. 1). Of these, 104 were able to answer the questionnaire
themselves; their mean score was 5.7 (out of 10, where a score of
10 indicates the highest burden); and 47 patients scored 7 or
higher. Of the 39 patients who were unable to answer the ques-
tions themselves, their caregivers answered the question on bur-
den of traveling with a mean score of 6.4 (Fig. 2). Data was
missing for eight patients.
Patients were also asked: “If traveling is a burden, what kind of
negative effect does it have lack of energy, fatigue, increase of spas-
ticity, increase of pain, or something else, please describe” (Fig. 3).
Although 11 patients scored 1 for burden of traveling, all
patients experienced one or more negative consequences. Most
patients experienced a lack of energy: 67% of the patients who
answered themselves (Fig. 3), and 64% of those whose caregivers
gave the answers on their behalf (Fig. 4).
Satisfaction
Patients and caregivers were positive about/satisﬁed with the
ITB on location. All patients reported increased convenience from
home-based Ambulant Care Clinic when compared to standard
aftercare by visiting a medical center.
Safety Evaluation
From a total of 6807 procedures, 11 adverse events (AE) and
9 SAE were registered. In one patient, a low reservoir alarm
3
Table 1. Demographic and Baseline Characteristics of the Aftercare Population (N = 239).
Disease MS SCI Stroke CP CRPS Other spinal Other cerebral Total
Male 26 31 7 44 0 8 18 134
Female 49 7 8 26 7 1 7 105
Total 75 38 15 70 7 9 25 239
Age (years)
Mean 54.1 55.7 55 29.6 55.3 61.5 34.4 45.58
Range (29–82) (22–81) (36–75) (8–70) (35–66) (42–82) (7–74) (7–82)
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Figure 1. Burden of traveling. [Color ﬁgure can be viewed at
wileyonlinelibrary.com]
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Figure 2. Answer on burden of traveling for patients. N=39. [Color ﬁgure can
be viewed at wileyonlinelibrary.com]
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created discomfort, but no harm. The wound management was
adjusted because of postoperative deviant wound edges. After
replacement of the pump, hematoma was reported postopera-
tively. One patient called in during duty hours with increased
spasticity; earlier that day the patient had undergone an access-
port procedure in the hospital. Investigation showed that, prior to
discharge, the priming bolus had been omitted. We discussed the
AE with the staff of the hospital, and an adaptation was made in
the work process to prevent this in future.
On two occasions, patients developed signs of underdosage
(a mild increase of spasticity and some sweating) between the
reﬁll intervals. Our protocol for this situation involves aspiration of
the reservoir content. In both instances, an empty reservoir was
found, probably due to an inadvertent pocket injection. The
pump was reﬁlled and a reduced dose adjustment was made.
Another patient was again initiated with oral baclofen, this hap-
pened after patient was relocated to another nursing home. The
local geriatrician telephoned our team reporting that the patient
was somnolent. Careful case history revealed double treatment,
and the oral baclofen was immediately discontinued.
SAE
In three other reﬁlls in obese patients, the pump was emptied
normally and indicated a correct needle position; however, later
on it appeared that the volume was injected outside the pump.
Over time dyspnea occurred (in 2 patients); in one case, this was
diagnosed as pneumonia and was not recognized by the patient’s
own geriatrician as a moderate withdrawal syndrome. Both
patients were hospitalized and both recovered fully after reﬁlling
the pump and dose adjustment. In one patient, there was an
increased discrepancy between the calculated and the actual
volume of the pump reservoir; this patient was referred to hospi-
tal and the pump was replaced. The older pump was returned to
Medtronic for further investigation.
The remaining SAEs occurred during the postoperative stage of
treatment, or after analysis of the patient’s ITB system. Due to
established collaboration with the neuromodulation centers, when
the SAE occurred, the ﬁrst contact with the patients was via the
ambulatory care clinic. The SAEs included meningitis, withdrawal
after incorrect pump programming, withdrawal after incorrect pump
reﬁlling with medication outside the pump, wound care, and liquor
leakage. In one SAE, a patient received the incorrect dosage of oral
medication from a caregiver in the nursing home, which led to hos-
pitalization and temporary cessation of ITB.
In total, 81 mistakes were reported. In the ﬁrst year, two inci-
dents were related to availability during duty hours; for this, an
immediate adaptation was made to the method of working.
Seven incidents of pump programming errors were reported; in
all cases, the double-check procedures prevented clinical manifes-
tations. In two cases, no order was made to prepare the syringe
before the pump was reﬁlled, which necessitated a rush order.
The highest number of incidents (21) was related to appoint-
ments, in particular when dose adaptations had to be made
between the normal scheduled procedures. On six occasions,
erroneous archiving of patients’ information in the electronic
patient dossier had to be corrected. On nine occasions, incidences
were reported due to delivery of the medication via the coopera-
tive pharmacist, and ﬁve incorrect preparations were found.
HFMEA and PRISMA Medical Analyses
The retrospective HFMEA analyses included improvements in
appointments, reporting delay, mistakes with patient data, and the
labeling ofmedication syringes. As prospective subjects, we performed
triage telephone call by the secretaries, transport, storage medication,
on-line connections, pump reﬁll procedure, and evaluation of the col-
laboration between Erasmus University Medical Center and Rehabilita-
tion Center Rijndam adult rehabilitation population. For the PRISMA
Medical analyses, we included; medication preparation and transport,
motor stall pump device, and reﬁlling outside the pump.
External Audits
The annual quality and safety certiﬁcation procedure performed
by KIWA showed no nonconformances. The degree of involve-
ment of the entire team was acknowledged. All 240 protocols and
procedure descriptions (with related descriptive ﬂow charts) were
described. The audit of the hygienist and the supervising pharma-
cist also showed no deviations. The healthcare insurance com-
pany “Achmea” granted a quality and safety award.
DISCUSSION
This study has shown the feasibility and safety of a home-based
Ambulatory Care Clinic for ITB management in a domestic setting
using telemedicine for real-time remote communication. Applying
the concept prevents burdensome traveling to a medical center
for severely handicapped patients. The importance of this was
shown by the satisfaction scores. An important ﬁnding was that
51.9% of the patients were living at home, which has a consider-
able beneﬁcial impact on the family’s daily life. The majority of
these patients received professional help for basic care. Routine
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Figure 3. Consequences of traveling, patients. N=104. [Color ﬁgure can be
viewed at wileyonlinelibrary.com]
0 5 10 15 20 25 30
Lac of energy
Fatique
Increase of spasticity
Increase of pain
Or something else
Number
B
ur
de
n
Figure 4. Caregivers’ answer consequences on burden of traveling for
patients. [Color ﬁgure can be viewed at wileyonlinelibrary.com]
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aftercare in a home setting is very important, particularly since
this avoids travel to an ITB center.
Telemedicine includes a growing variety of applications and
services to provide equal access to medical support, irrespective
of geographic circumstances (11). This term covers our activities
and implies a more speciﬁc application using interactive video
communication (13). The present study was performed in a small
country with relatively short travel distances. In less densely popu-
lated countries with greater travel distances, the related problems
might be more extensive.
In our study, a lower incidence of complications was observed
than in the subject literature. Whether there is a speciﬁc relationship
between the treatment in the hospital or at home was not part of
the scope of our study, so that we cannot comment on the matter.
Our concept could help to optimize the quality of life of patients
who suffer severely. This was demonstrated by the extended growth
of the test population; we performed aftercare in ≥25% of the entire
ITB population in the Netherlands. The prevention of substantial
adverse events demonstrated the value of the double-check proce-
dures. We agree with Bradford et al. (14) that providing care at home
should not involve a reduction of standards, implying that the dou-
ble check should be included. The feasibility of the use of a laptop
computer or tablet (14) to conduct double-checks using an e-health
technique has been demonstrated without contravention of the exis-
ting standards. We found that obesity played an important role in
the three adverse events during pump reﬁll (15). Finding the small
reﬁll membrane and the risk of needle dislocation during syringe
changes are important parts of the process. Particularly in a 40-ml
pump, a change of syringe could result in an (unrecognized) injec-
tion outside the pump. Good collaboration in case of trouble shoot-
ing with a medical center is indispensable. Direct referral of patients
in case of problems is also very important. On the other hand, it is
important that the patient stays as brieﬂy as possible in a medical
center; aftercare in their own surroundings is guaranteed by a
home-based Ambulatory Care Clinic. Although time consuming, dur-
ing a process of continuous improvement of treatment, the Ambula-
tory Care Clinic recognized that the HFMEA and the extended
PRISMA Medical analyses should be conducted in routine practice.
A limitation of our study is that due to its retrospective character,
we were not able to make a comparison of the adverse event data
of the home-based ambulatory clinic with hospital-based data. This
might have created a stronger argument that the home-based
ambulatory group can be treated as safely as the hospital-based
group. The problem is that the hospital-based patients are treated in
different hospitals, and unfortunately, we do not possess the rele-
vant data. Further research into this is therefore recommended.
CONCLUSIONS
The concept of home-based Ambulatory Care Clinic has clearly
shown its feasibility and safety and can prevent a patient’s burdensome
traveling to a medical center for pump reﬁlls and dose adjustments.
The encrypted bidirectional videoconferencing with 4G connection
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Figure 5. Procedure Reﬁlling Synchromed II pump, ITB.
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has proven its reliability and enabled communication with patients,
and the performance of double checks on medication and proce-
dures. Close cooperation with a neuromodulation center in case of
problems is indispensable and can be arranged in chain-based care.
In this way, clinical standards can be preserved for complex treat-
ment. Themethod can be valuable for application elsewhere, partic-
ularly in countries with long traveling distances between care
centers. The Dutch Healthcare Authorities are convinced about the
research results and have included ITB-aftercare, performed by a
home-based Ambulatory Care Clinic, as a ﬁxed component in
healthcare with associated reimbursement structure.
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